Skeletal Fluorosis & Other Toxic Osteopathies (Hypervitaminosis A/D, Aluminium Bone Disease)

• Fluoride stimulates osteoblasts. Fluoride is a direct osteoblast mitogen, driving bone formation and the increased density - which is why it was once trialled for osteoporosis; but the bone laid down is abnormal in quality (fragile), so density rises without a matching gain in strength.
• Fluorapatite and the mineralisation defect. Fluoride substitutes into hydroxyapatite to form fluorapatite - larger, less soluble, more acid-resistant crystals (the basis of caries prevention) - but the rapid, abnormal mineralisation leaves a defect with excess osteoid (the osteomalacic component), giving the 'dense but weak' paradox.
• Secondary hyperparathyroidism and the dose spectrum. Fluoride also binds calcium, tending to secondary hyperparathyroidism. Lower chronic exposure during tooth development causes dental fluorosis (mottled enamel) in children; higher cumulative exposure over years causes skeletal fluorosis in adults.

• Lead lines. In chronically lead-exposed growing children, dense transverse metaphyseal bands appear at the fastest-growing metaphyses (distal femur, proximal tibia, distal radius). The density is not deposited lead but disordered metaphyseal remodelling - lead inhibits osteoclastic resorption of the calcified cartilage, leaving a band of retained mineral; adults with mature skeletons do not form them. They are a radiographic marker of chronic exposure (plumbism).
• Plumbism. Lead lines accompany the systemic features of lead poisoning: abdominal colic, encephalopathy (children), motor neuropathy (wrist/foot drop in adults), microcytic anaemia with basophilic stippling, a gum (Burton) line and nephropathy.
• Other heavy metals. Historic examples include phosphorus ('phossy jaw' - osteonecrosis of the mandible in match workers) and bismuth (metaphyseal bands like lead lines).

"Partially reversible over years" is the usual teaching, and the one case with a decade of documented follow-up shows it is true but far slower and less complete than that phrase suggests. A 52-year-old man with axial osteosclerosis and neck immobility, whose fluoride source proved to be surreptitious toothpaste ingestion, was monitored for ten years after the source was removed.

• Biochemistry corrects in months. Urine fluoride fell from 26 mg/L to 16 within 3 months and 3.9 at 14 months; serum fluoride normalised within 8 months; bone turnover markers corrected by 14 months. So the laboratory picture improves quickly and can mislead you into thinking the skeleton has recovered.
• The skeleton takes decades. At 9 years, lumbar spine bone density had fallen 23.6% and femoral neck 15.1% - yet the Z-scores were still +9.3 and +4.8, having started at +14.3 and +6.6. Bone fluoride at 8.5 years was still 1.15% against a reference of less than 0.1% - a 36% reduction, but still roughly ten times normal. Radiographs showed decreased trabecular sclerosis and some reduction in sacrospinous ligament ossification, not resolution.
• The osteomalacia is quantifiable and it does recover. The initial biopsy showed cancellous bone volume 4.5 times, cortical width 3.2 times, and osteoid thickness 25 times the reference mean, with wide diffuse tetracycline uptake confirming osteomalacia. By 8.5 years osteoid surface and thickness had normalised with distinct double labels - so the mineralisation defect, the part that makes the bone fragile, is the component that actually reverses.
• Symptoms resolved and he never fractured. All arthralgias resolved within 2 years.
• But watch the kidney. New-onset nephrolithiasis appeared within 9 months of stopping the fluoride and became a chronic problem, with creatinine drifting from 1.0 to 1.3 mg/dL over the decade. Patients should be monitored for stones during the recovery phase - the mobilised fluoride load has to be excreted.

Exposure is necessary but not sufficient, and this is worth knowing because it explains the clinical observation that individuals in the same village with the same water supply are affected to very different degrees.

• The scale of the problem. Fluorosis is endemic in at least 25 countries, with China and India the worst affected, and dental, skeletal and non-skeletal forms affect millions of people. Skeletal fluorosis is rare in the United States and western Europe - which is why it is easily missed there, and why the exposure history matters more than the radiograph.
• Genetic susceptibility modifies risk. Genetic-epidemiological studies have associated polymorphisms in candidate genes - COL1A2, the calcitonin receptor, the oestrogen receptor, COMT, GSTP1, MMP-2, prolactin, the vitamin D receptor and myeloperoxidase - with differing susceptibility among individuals in the same community under the same environmental exposure.
• How firm is this? These are association studies in candidate genes, a design notoriously prone to false-positive findings and poor replication. Treat the principle - that host genetic background modifies susceptibility at equal exposure - as reasonable, and treat any individual gene on that list as unconfirmed. No genetic test is used clinically, and susceptibility genotype does not change management.